News Column

Recent Findings by J.T. Hung and Colleagues in DNA Vaccines Provides New Insights (Potent adjuvant effects of novel NKT stimulatory glycolipids on...

August 6, 2014



Recent Findings by J.T. Hung and Colleagues in DNA Vaccines Provides New Insights (Potent adjuvant effects of novel NKT stimulatory glycolipids on hemagglutinin based DNA vaccine for H5N1 influenza virus)

By a News Reporter-Staff News Editor at Vaccine Weekly -- Researchers detail new data in Biotechnology. According to news reporting out of Taoyuan, Taiwan, by NewsRx editors, research stated, "H5N1 influenza virus is a highly pathogenic virus, posing a pandemic threat. Previously, we showed that phenyl analogs of alpha-galactosylceramide (alpha-GalCer) displayed greater NKT stimulation than alpha-GalCer."

Our news journalists obtained a quote from the research, "Here, we examined the adjuvant effects of one of the most potent analogs, C34, on consensus hemagglutinin based DNA vaccine (pCHA5) for H5N1 virus. Upon intramuscular electroporation of mice with pCHA5 with/without various alpha-GalCer analogs, C34-adjuvanted group developed the highest titer against consensus H5 and more HA-specific IFN-gamma secreting CD8 cells (203 +/- 13.5) than pCHA5 alone (152.6 +/- 13.7, p< 0.05). Upon lethal challenge of NIBRG-14 virus, C34-adjuvanted group (84.6%) displayed higher survival rate than pCHA5 only group (46.1%). In the presence of C34 as adjuvant, the antisera displayed broader and greater neutralizing activities against virions pseudotyped with HA of clade 1, and 2.2 than pCHA5 only group. Moreover, to simulate an emergency response to a sudden H5N1 outbreak, we injected mice intramuscularly with single dose of a new consensus H5 (pCHA5-II) based on 1192 full-length H5 sequences, with C34 as adjuvant. The latter not only enhanced the humoral immune response and protection against virus challenge, but also broadened the spectrum of neutralization against pseudotyped HA viruses."

According to the news editors, the research concluded: "Our vaccine strategy can be easily implemented for any H5N1 virus outbreak by single IM injection of a consensus H5 DNA vaccine based on updated HA sequences using C34 as an adjuvant."

For more information on this research see: Potent adjuvant effects of novel NKT stimulatory glycolipids on hemagglutinin based DNA vaccine for H5N1 influenza virus. Antiviral Research, 2014;107():110-118. Antiviral Research can be contacted at: Elsevier Science Bv, PO Box 211, 1000 Ae Amsterdam, Netherlands. (Elsevier - www.elsevier.com; Antiviral Research - www.elsevier.com/wps/product/cws_home/521852)

Our news journalists report that additional information may be obtained by contacting J.T. Hung, Chang Gung Mem Hosp Linkou, Inst Stem Cell & Translat Canc Res, Taoyuan 333, Taiwan. Additional authors for this research include Y.C. Tsai, W.D. Lin, J.T. Jan, K.H. Lin, J.R. Huang, J.Y. Cheng, M.W. Chen, C.H. Wong and A.L. Yu (see also Biotechnology).

Keywords for this news article include: Asia, Biotechnology, Taiwan, Taoyuan, Virology, Viral DNA, RNA Viruses, Vaccination, DNA Research, DNA Vaccines, Immunization, Viral Vaccines, Medical Devices, Orthomyxoviridae, Influenza Vaccines, Synthetic Vaccines, Vertebrate Viruses, Biological Products, Influenza A Virus Subtype H5N1

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Vaccine Weekly


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters